$REPL
Replimune Group, Inc.

2022 Q4 Form 10-Q Financial Statement

#000173795322000023 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.37M $12.75M
YoY Change 9.9% 36.38%
% of Gross Profit
Research & Development $30.26M $28.83M
YoY Change 56.36% 44.88%
% of Gross Profit
Depreciation & Amortization $682.0K $617.0K
YoY Change 24.45% 15.98%
% of Gross Profit
Operating Expenses $41.63M $41.58M
YoY Change 40.18% 42.17%
Operating Profit -$41.63M -$41.58M
YoY Change 40.18% 42.17%
Interest Expense $1.186M $562.0K
YoY Change -353.42% -217.82%
% of Operating Profit
Other Income/Expense, Net $1.940M -$1.523M
YoY Change 7983.33% 1310.19%
Pretax Income -$39.69M -$43.10M
YoY Change 33.75% 46.83%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$39.70M -$43.10M
YoY Change 33.79% 46.82%
Net Earnings / Revenue
Basic Earnings Per Share -$0.69 -$0.79
Diluted Earnings Per Share -$0.69 -$0.79
COMMON SHARES
Basic Shares Outstanding 49.74M shares 49.31M shares
Diluted Shares Outstanding 57.86M shares 54.77M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $616.4M $371.8M
YoY Change 46.7% -14.68%
Cash & Equivalents $206.7M $88.93M
Short-Term Investments $409.7M $282.9M
Other Short-Term Assets $5.591M $4.981M
YoY Change 3.29% -13.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $624.0M $379.4M
YoY Change 45.86% -14.63%
LONG-TERM ASSETS
Property, Plant & Equipment $7.679M $7.910M
YoY Change 3.6% 10.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.636M $1.636M
YoY Change 0.0% 0.0%
Total Long-Term Assets $54.59M $56.71M
YoY Change -5.04% -4.02%
TOTAL ASSETS
Total Short-Term Assets $624.0M $379.4M
Total Long-Term Assets $54.59M $56.71M
Total Assets $678.6M $436.1M
YoY Change 39.83% -13.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.648M $3.996M
YoY Change -6.99% 26.7%
Accrued Expenses $19.05M $14.43M
YoY Change 74.8% 43.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.619M $2.600M
YoY Change 2.99% 3.01%
Total Short-Term Liabilities $26.46M $23.54M
YoY Change 44.68% 41.48%
LONG-TERM LIABILITIES
Long-Term Debt $52.48M $24.21M
YoY Change 114.18% -1.58%
Other Long-Term Liabilities $4.265M $4.280M
YoY Change -14.37% -11.24%
Total Long-Term Liabilities $56.74M $28.49M
YoY Change 92.46% -3.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.46M $23.54M
Total Long-Term Liabilities $56.74M $28.49M
Total Liabilities $83.21M $52.02M
YoY Change 74.17% 12.97%
SHAREHOLDERS EQUITY
Retained Earnings -$436.2M -$396.6M
YoY Change 56.06% 58.75%
Common Stock $57.00K $50.00K
YoY Change 21.28% 6.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $595.3M $384.1M
YoY Change
Total Liabilities & Shareholders Equity $678.6M $436.1M
YoY Change 39.83% -13.38%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$39.70M -$43.10M
YoY Change 33.79% 46.82%
Depreciation, Depletion And Amortization $682.0K $617.0K
YoY Change 24.45% 15.98%
Cash From Operating Activities -$28.59M -$33.21M
YoY Change 55.82% 44.64%
INVESTING ACTIVITIES
Capital Expenditures $555.0K -$396.0K
YoY Change -219.35% -7.48%
Acquisitions
YoY Change
Other Investing Activities -$124.5M $432.0K
YoY Change 861.37% -104.07%
Cash From Investing Activities -$125.1M $36.00K
YoY Change 832.2% -100.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 271.4M 7.423M
YoY Change 6738.88% 545.48%
NET CHANGE
Cash From Operating Activities -28.59M -33.21M
Cash From Investing Activities -125.1M 36.00K
Cash From Financing Activities 271.4M 7.423M
Net Change In Cash 117.7M -25.75M
YoY Change -523.56% -21.64%
FREE CASH FLOW
Cash From Operating Activities -$28.59M -$33.21M
Capital Expenditures $555.0K -$396.0K
Free Cash Flow -$29.14M -$32.81M
YoY Change 62.97% 45.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Entity Central Index Key
EntityCentralIndexKey
0001737953
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38596
dei Entity Registrant Name
EntityRegistrantName
REPLIMUNE GROUP, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2082553
dei Entity Address Address Line1
EntityAddressAddressLine1
500 Unicorn Park
dei Entity Address City Or Town
EntityAddressCityOrTown
Woburn
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01801
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
222-9600
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
REPL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49739407 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88930000 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105948000 usd
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
282890000 usd
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
289707000 usd
CY2022Q3 repl Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
2589000 usd
CY2022Q1 repl Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
3055000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4981000 usd
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5267000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
379390000 usd
CY2022Q1 us-gaap Assets Current
AssetsCurrent
403977000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7910000 usd
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7933000 usd
CY2022Q3 repl Research And Development Incentives Receivable Noncurrent
ResearchAndDevelopmentIncentivesReceivableNoncurrent
1296000 usd
CY2022Q1 repl Research And Development Incentives Receivable Noncurrent
ResearchAndDevelopmentIncentivesReceivableNoncurrent
0 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1636000 usd
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1636000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4984000 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5552000 usd
CY2022Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
40879000 usd
CY2022Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
42094000 usd
CY2022Q3 us-gaap Assets
Assets
436095000 usd
CY2022Q1 us-gaap Assets
Assets
461192000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3996000 usd
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3732000 usd
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15939000 usd
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13392000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1002000 usd
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1070000 usd
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2600000 usd
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2562000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23537000 usd
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
20756000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4280000 usd
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4801000 usd
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
24206000 usd
CY2022Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
24406000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
52023000 usd
CY2022Q1 us-gaap Liabilities
Liabilities
49963000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
us-gaap Operating Income Loss
OperatingIncomeLoss
-56628000 usd
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49739407 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49739407 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47338660 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47338660 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
50000 usd
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
47000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
777650000 usd
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
723359000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396559000 usd
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-311204000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2931000 usd
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-973000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
384072000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
411229000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
436095000 usd
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
461192000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28834000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19902000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58312000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38456000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12745000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9345000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24143000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18172000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
41579000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
29247000 usd
us-gaap Operating Expenses
OperatingExpenses
82455000 usd
us-gaap Operating Expenses
OperatingExpenses
56628000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-41579000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29247000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-82455000 usd
CY2022Q3 repl Research And Development Incentives Income
ResearchAndDevelopmentIncentivesIncome
574000 usd
CY2021Q3 repl Research And Development Incentives Income
ResearchAndDevelopmentIncentivesIncome
725000 usd
repl Research And Development Incentives Income
ResearchAndDevelopmentIncentivesIncome
1425000 usd
repl Research And Development Incentives Income
ResearchAndDevelopmentIncentivesIncome
1513000 usd
CY2022Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1112000 usd
CY2021Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
80000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1455000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
172000 usd
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
550000 usd
CY2021Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
557000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1102000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1115000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2659000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-356000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4678000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-608000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1523000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-108000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2900000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-38000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-43102000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29355000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85355000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-56666000 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54770291 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54770291 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52081325 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52081325 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54492395 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54492395 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51962795 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51962795 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-43102000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-29355000 usd
us-gaap Net Income Loss
NetIncomeLoss
-85355000 usd
us-gaap Net Income Loss
NetIncomeLoss
-56666000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2330000 usd
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
219000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4067000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
443000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
0 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
81000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-163000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-40000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40691000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29136000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81451000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56263000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
411229000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
31037000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1737000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-244000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1562000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7194000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-42253000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
410262000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6401000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2330000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
81000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1108000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6992000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-43102000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
384072000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
498728000 usd
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
224000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-40000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1173000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6250000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-27311000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
479024000 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
219000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1211000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6313000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-29355000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
457412000 usd
us-gaap Profit Loss
ProfitLoss
-85355000 usd
us-gaap Profit Loss
ProfitLoss
-56666000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
14186000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12563000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1237000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1050000 usd
repl Net Amortization Of Premiums And Discounts On Short Term Investments
NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments
161000 usd
repl Net Amortization Of Premiums And Discounts On Short Term Investments
NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments
-1284000 usd
repl Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
1417000 usd
repl Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
1513000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-159000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1252000 usd
repl Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-252000 usd
repl Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-217000 usd
repl Increase Decrease Finance Lease Right Of Use Asset
IncreaseDecreaseFinanceLeaseRightOfUseAsset
-1214000 usd
repl Increase Decrease Finance Lease Right Of Use Asset
IncreaseDecreaseFinanceLeaseRightOfUseAsset
-1214000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
698000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
750000 usd
repl Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
2779000 usd
repl Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
1293000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-257000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-215000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66665000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41275000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1464000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
719000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
193685000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
111356000 usd
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
200500000 usd
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
128015000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5351000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15940000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37438000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
163000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
114000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2670000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2384000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
39945000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2270000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4351000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
516000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17018000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22549000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
107584000 usd
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
184154000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90566000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
161605000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
96000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
96000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
177000 usd
us-gaap Nature Of Operations
NatureOfOperations
Nature of the business<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Replimune Group, Inc. (the “Company”) is a clinical-stage biotechnology company committed to applying its leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through its novel tumor-directed oncolytic immunotherapies. The Company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Replimune Group, Inc., whose predecessor was founded in 2015, is the parent company of its wholly owned, direct and indirect subsidiaries: Replimune Limited (“Replimune UK”); Replimune, Inc. (“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, third-party intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since its inception, including net losses of $43.1 million and $29.4 million for the three months ended September 30, 2022 and 2021, respectively and net losses of $85.4 million and $56.7 million for the six months ended September 30, 2022 and 2021, respectively. In addition, as of September 30, 2022, the Company had an accumulated deficit of $396.6 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of these consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 coronavirus</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus, which causes the disease known as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 coronavirus has spread globally. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic and the U.S. government imposed travel restrictions on travel between the United States, Europe and certain other countries. The impact of this pandemic has been, and may continue to be, extensive in many aspects of society, which has resulted, and may continue to result, in significant disruptions to the global economy as well as businesses and capital markets around the world.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is continuing to generally monitor the spread of COVID-19 and, throughout the pandemic, has implemented measures designed to comply with applicable federal, state and local guidelines, as well as care for the Company's employee's health and well-being. The Company will continue to examine its protocols as the pandemic and health guidance evolves. The COVID-19 pandemic continues to affect the United States and global economies and has affected and may continue to affect the Company's operations and those of third parties on which it relies, including by causing disruptions in our raw material and supply of other materials, the manufacturing of its product candidates and its developing commercialization processes. However, the extent of these delays is currently unknown and has and will likely continue to vary. In addition, the Company may incur unforeseen costs as a result of disruptions in raw material supplies, clinical product supplies, and preclinical studies or clinical trial delays. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken in an effort to contain it or to potentially treat or continue to vaccinate against COVID-19 and the economic impact on local, regional, national and international markets. The Company continues to monitor this situation and the possible effects on its financial condition, liquidity, operations, suppliers, supplies, industry and workforce.</span></div>
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-43100000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-29400000 usd
us-gaap Net Income Loss
NetIncomeLoss
-85400000 usd
us-gaap Net Income Loss
NetIncomeLoss
-56700000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including, expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19. The Company has made estimates of the impact of COVID-19 within the Company's financial statements and there may be changes to those estimates in future periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management evaluates its estimates in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</span></div>
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13942000 usd
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12728000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6032000 usd
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4795000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7910000 usd
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7933000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
617000 usd
us-gaap Depreciation
Depreciation
1237000 usd
CY2021Q3 us-gaap Depreciation
Depreciation
532000 usd
us-gaap Depreciation
Depreciation
1050000 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 repl Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
8224000 usd
CY2022Q1 repl Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
5882000 usd
CY2022Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4439000 usd
CY2022Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5569000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
760000 usd
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
621000 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2516000 usd
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1320000 usd
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15939000 usd
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13392000 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
340000 shares
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6700000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
200000 usd
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107782000 usd
CY2020Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
269975000 usd
CY2020Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3084238 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2200000 shares
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6992000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6313000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14186000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12563000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6992000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6313000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14186000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12563000 usd
CY2017Q3 repl Conversion Of Stock Ratio
ConversionOfStockRatio
1
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5284238 shares
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5284238 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
125000000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0261
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0111
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.755
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.802
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6514334 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.78
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M3D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30358000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1325894 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.15
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
212280 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
12.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
214482 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
22.30
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7413466 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M21D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30477000 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3645749 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.85
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M21D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
24875000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4291654 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.50
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M21D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
26428000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.20
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
22.25
CY2022Q3 repl Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
1200000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-43102000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29355000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85355000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-56666000 usd
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54770291 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54770291 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52081325 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52081325 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54492395 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54492395 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51962795 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51962795 shares
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5284238 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7910810 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7910810 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7495441 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7495441 shares
CY2022Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
607000 usd
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
607000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1214000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1214000 usd
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
550000 usd
CY2021Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
557000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1102000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1115000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
252000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
245000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
511000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
487000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
1409000 usd
CY2021Q3 us-gaap Lease Cost
LeaseCost
1409000 usd
us-gaap Lease Cost
LeaseCost
2827000 usd
us-gaap Lease Cost
LeaseCost
2816000 usd
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
550000 usd
CY2021Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
557000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1102000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1115000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
500000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
1297000 usd
CY2022Q3 repl Operating And Finance Lease Liability Payments Remainder Of Fiscal Year
OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
1797000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1007000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
2639000 usd
CY2022Q3 repl Operating And Finance Lease Liability Payments Due Next Twelve Months
OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths
3646000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1016000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
2718000 usd
CY2022Q3 repl Operating And Finance Lease Liability Payments Due Year Two
OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo
3734000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1026000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
2799000 usd
CY2022Q3 repl Operating And Finance Lease Liability Payments Due Year Three
OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree
3825000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
997000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
2883000 usd
CY2022Q3 repl Operating Finance Lease Liability Payments Due Year Four
OperatingFinanceLeaseLiabilityPaymentsDueYearFour
3880000 usd
CY2022Q3 repl Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
2755000 usd
CY2022Q3 repl Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
38022000 usd
CY2022Q3 repl Operating And Finance Lease Liability Payments Due After Year Four
OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour
40777000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7301000 usd
CY2022Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
50358000 usd
CY2022Q3 repl Operating And Finance Lease Liability Payments Due
OperatingAndFinanceLeaseLiabilityPaymentsDue
57659000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2019000 usd
CY2022Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
23552000 usd
CY2022Q3 repl Operating And Finance Lease Liability Undiscounted Excess Amount
OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount
25571000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5282000 usd
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
26806000 usd
CY2022Q3 repl Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
32088000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4984000 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5552000 usd
CY2022Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
40879000 usd
CY2022Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
42094000 usd
CY2022Q3 repl Lease Right Of Use Asset
LeaseRightOfUseAsset
45863000 usd
CY2022Q1 repl Lease Right Of Use Asset
LeaseRightOfUseAsset
47646000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1002000 usd
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1070000 usd
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2600000 usd
CY2022Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2562000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4280000 usd
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4801000 usd
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
24206000 usd
CY2022Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
24406000 usd
CY2022Q3 repl Lease Liability
LeaseLiability
32088000 usd
CY2022Q1 repl Lease Liability
LeaseLiability
32839000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
466000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
487000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1102000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1115000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
163000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
114000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M18D
CY2022Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P16Y9M18D
CY2021Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P17Y9M18D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
CY2022Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.083
CY2021Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.083
CY2022Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
1209000 usd
CY2022Q1 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
1951000 usd
repl Number Of Operating Geographic Regions
NumberOfOperatingGeographicRegions
2 region
CY2022Q3 us-gaap Noncurrent Assets
NoncurrentAssets
7910000 usd
CY2022Q1 us-gaap Noncurrent Assets
NoncurrentAssets
7933000 usd

Files In Submission

Name View Source Status
0001737953-22-000023-index-headers.html Edgar Link pending
0001737953-22-000023-index.html Edgar Link pending
0001737953-22-000023.txt Edgar Link pending
0001737953-22-000023-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hercules-replimunexloana.htm Edgar Link pending
hercules-replimunexloana001.jpg Edgar Link pending
hercules-replimunexloana002.jpg Edgar Link pending
hercules-replimunexloana003.jpg Edgar Link pending
hercules-replimunexloana004.jpg Edgar Link pending
hercules-replimunexloana005.jpg Edgar Link pending
hercules-replimunexloana006.jpg Edgar Link pending
hercules-replimunexloana007.jpg Edgar Link pending
hercules-replimunexloana008.jpg Edgar Link pending
hercules-replimunexloana009.jpg Edgar Link pending
hercules-replimunexloana010.jpg Edgar Link pending
hercules-replimunexloana011.jpg Edgar Link pending
hercules-replimunexloana012.jpg Edgar Link pending
hercules-replimunexloana013.jpg Edgar Link pending
hercules-replimunexloana014.jpg Edgar Link pending
hercules-replimunexloana015.jpg Edgar Link pending
hercules-replimunexloana016.jpg Edgar Link pending
hercules-replimunexloana017.jpg Edgar Link pending
hercules-replimunexloana018.jpg Edgar Link pending
hercules-replimunexloana019.jpg Edgar Link pending
hercules-replimunexloana020.jpg Edgar Link pending
hercules-replimunexloana021.jpg Edgar Link pending
hercules-replimunexloana022.jpg Edgar Link pending
hercules-replimunexloana023.jpg Edgar Link pending
hercules-replimunexloana024.jpg Edgar Link pending
hercules-replimunexloana025.jpg Edgar Link pending
hercules-replimunexloana026.jpg Edgar Link pending
hercules-replimunexloana027.jpg Edgar Link pending
hercules-replimunexloana028.jpg Edgar Link pending
hercules-replimunexloana029.jpg Edgar Link pending
hercules-replimunexloana030.jpg Edgar Link pending
hercules-replimunexloana031.jpg Edgar Link pending
hercules-replimunexloana032.jpg Edgar Link pending
hercules-replimunexloana033.jpg Edgar Link pending
hercules-replimunexloana034.jpg Edgar Link pending
hercules-replimunexloana035.jpg Edgar Link pending
hercules-replimunexloana036.jpg Edgar Link pending
hercules-replimunexloana037.jpg Edgar Link pending
hercules-replimunexloana038.jpg Edgar Link pending
hercules-replimunexloana039.jpg Edgar Link pending
hercules-replimunexloana040.jpg Edgar Link pending
hercules-replimunexloana041.jpg Edgar Link pending
hercules-replimunexloana042.jpg Edgar Link pending
hercules-replimunexloana043.jpg Edgar Link pending
hercules-replimunexloana044.jpg Edgar Link pending
hercules-replimunexloana045.jpg Edgar Link pending
hercules-replimunexloana046.jpg Edgar Link pending
hercules-replimunexloana047.jpg Edgar Link pending
hercules-replimunexloana048.jpg Edgar Link pending
hercules-replimunexloana049.jpg Edgar Link pending
hercules-replimunexloana050.jpg Edgar Link pending
hercules-replimunexloana051.jpg Edgar Link pending
hercules-replimunexloana052.jpg Edgar Link pending
hercules-replimunexloana053.jpg Edgar Link pending
hercules-replimunexloana054.jpg Edgar Link pending
hercules-replimunexloana055.jpg Edgar Link pending
hercules-replimunexloana056.jpg Edgar Link pending
hercules-replimunexloana057.jpg Edgar Link pending
hercules-replimunexloana058.jpg Edgar Link pending
hercules-replimunexloana059.jpg Edgar Link pending
hercules-replimunexloana060.jpg Edgar Link pending
hercules-replimunexloana061.jpg Edgar Link pending
hercules-replimunexloana062.jpg Edgar Link pending
hercules-replimunexloana063.jpg Edgar Link pending
hercules-replimunexloana064.jpg Edgar Link pending
hercules-replimunexloana065.jpg Edgar Link pending
hercules-replimunexloana066.jpg Edgar Link pending
hercules-replimunexloana067.jpg Edgar Link pending
hercules-replimunexloana068.jpg Edgar Link pending
hercules-replimunexloana069.jpg Edgar Link pending
hercules-replimunexloana070.jpg Edgar Link pending
hercules-replimunexloana071.jpg Edgar Link pending
hercules-replimunexloana072.jpg Edgar Link pending
hercules-replimunexloana073.jpg Edgar Link pending
hercules-replimunexloana074.jpg Edgar Link pending
hercules-replimunexloana075.jpg Edgar Link pending
hercules-replimunexloana076.jpg Edgar Link pending
hercules-replimunexloana077.jpg Edgar Link pending
hercules-replimunexloana078.jpg Edgar Link pending
hercules-replimunexloana079.jpg Edgar Link pending
hercules-replimunexloana080.jpg Edgar Link pending
hercules-replimunexloana081.jpg Edgar Link pending
hercules-replimunexloana082.jpg Edgar Link pending
hercules-replimunexloana083.jpg Edgar Link pending
hercules-replimunexloana084.jpg Edgar Link pending
hercules-replimunexloana085.jpg Edgar Link pending
hercules-replimunexloana086.jpg Edgar Link pending
hercules-replimunexloana087.jpg Edgar Link pending
hercules-replimunexloana088.jpg Edgar Link pending
hercules-replimunexloana089.jpg Edgar Link pending
hercules-replimunexloana090.jpg Edgar Link pending
hercules-replimunexloana091.jpg Edgar Link pending
hercules-replimunexloana092.jpg Edgar Link pending
hercules-replimunexloana093.jpg Edgar Link pending
hercules-replimunexloana094.jpg Edgar Link pending
hercules-replimunexloana095.jpg Edgar Link pending
hercules-replimunexloana096.jpg Edgar Link pending
hercules-replimunexloana097.jpg Edgar Link pending
hercules-replimunexloana098.jpg Edgar Link pending
hercules-replimunexloana099.jpg Edgar Link pending
hercules-replimunexloana100.jpg Edgar Link pending
hercules-replimunexloana101.jpg Edgar Link pending
hercules-replimunexloana102.jpg Edgar Link pending
hercules-replimunexloana103.jpg Edgar Link pending
hercules-replimunexloana104.jpg Edgar Link pending
hercules-replimunexloana105.jpg Edgar Link pending
hercules-replimunexloana106.jpg Edgar Link pending
hercules-replimunexloana107.jpg Edgar Link pending
hercules-replimunexloana108.jpg Edgar Link pending
hercules-replimunexloana109.jpg Edgar Link pending
hercules-replimunexloana110.jpg Edgar Link pending
hercules-replimunexloana111.jpg Edgar Link pending
hercules-replimunexloana112.jpg Edgar Link pending
hercules-replimunexloana113.jpg Edgar Link pending
hercules-replimunexloana114.jpg Edgar Link pending
hercules-replimunexloana115.jpg Edgar Link pending
hercules-replimunexloana116.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
repl-20220930.htm Edgar Link pending
repl-20220930.xsd Edgar Link pending
repl-93022x10qxex311.htm Edgar Link pending
repl-93022x10qxex312.htm Edgar Link pending
repl-93022x10qxex321.htm Edgar Link pending
repl-93022x10qxex322.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
repl-20220930_cal.xml Edgar Link unprocessable
repl-20220930_lab.xml Edgar Link unprocessable
repl-20220930_pre.xml Edgar Link unprocessable
repl-20220930_htm.xml Edgar Link completed
repl-20220930_def.xml Edgar Link unprocessable